StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Nektar Therapeutics's EV/EBITDA was 5.4× on Jul 31, 2019, against 28.3× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2019Jul 31, 20195.4×−0.1
2018Dec 31, 20185.5×−22.8
2015Oct 30, 201528.3×–

More Nektar Therapeutics figures

See a number that looks wrong?